ArticleJournal of breast cancer2022

Biomarkers That Predict an Unclear Benefit From Adjuvant Trastuzumab, Pertuzumab and Pembrolizumab When Those Same Drugs Were Given Neoadjuvantly.

Steven SorscherPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.